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ABSTRACT
Bacillus anthracis secretes three secretary proteins; lethal factor (LF), protective 
antigen (PA) and edema factor (EF). The LF has ability to check proliferation of 
mammary tumors, chiefly depending on mitogen activated protein kinase (MAPK) 
signaling pathway. Evaluation of therapeutic potential of recombinant LF (rLF), 
recombinant PA (rPA) and lethal toxin (rLF + rPA = LeTx) on the primary mammary 
ductal carcinoma cells revealed significant (p < 0.01) reduction in proliferation 
of tumor cells with mean inhibition indices of 28.0 ± 1.37% and 19.6 ± 1.47% 
respectively. However, treatment with rPA alone had no significant anti-proliferative 
effect as evident by low mean inhibition index of 3.4 ± 3.87%. The higher inhibition 
index observed for rLF alone as compared to LeTx is contrary to the existing 
knowledge on LF, which explains the requirement of PA dependent endocytosis for 
its enzymatic activity. Therefore, the plausible existence of PA independent mode of 
action of LF including direct receptor mediated endocytosis or modulation of signal 
transduction cascade via unknown means is hypothesized. In silico protein docking 
analysis of other cellular receptors for any plausibility to play the role of receptor 
for LF revealed c-Met receptor  showing strongest affinity for LF (H bond = 19; Free 
energy = −773.96), followed by nerve growth factor receptor (NGFR) and  human 
epidermal growth factor receptor (HER)-1. The study summarizes the use of rLF or 
LeTx as therapeutic molecule against primary mammary ductal carcinoma cells and 
also the c-Met as potential alternative receptor for LF to mediate and modulate PA 
independent signal transduction.
INTRODUCTION
Cancer remains a deadly malady despite several 
scientific advances and is one of the leading causes 
of deaths and high sufferings to the mankind. Though 
conventional therapies including of radiotherapy, 
chemotherapy and surgery are being followed widely; 
however due to their some limitations and side effects, 
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researchers are continuously in the search of novel 
and alternative/complementary therapeutic options 
for countering various kinds of cancers and tumorous 
conditions. Some of such therapeutic regimens being 
explored include hormones inhibitors, immunotherapy 
(adjuvants, cytokines, TLR-agonists, immune-checkpoint 
inhibitors), apoptins (selective anti-cancer viral proteins), 
cryotherapy, molecular therapy (gene therapy, RNAi, 
CRISPR, Phages), homing peptides, herbs and plant 
metabolites, nanotechnology-based drug delivery as 
well as tumor vaccines, DNAzymes, HSP90 chaperone 
complex inhibitors, probiotic therapy, ribosome 
inactivating plant toxins, zootoxins derived from bees, 
snakes or scorpion, sponge toxins like agelasine B, or 
bacterial toxins and many others [1–10]. Several bacterial 
toxins are manipulated to specifically target tumor cells. 
These toxins include Clostridium difficile toxin [11, 12] 
Shiga-like toxin 1 [13, 14], Pseudomonas exotoxin A 
(PE) [15], Pertussis toxin [16] etc. Likewise, the same has 
been observed with lethal toxin of Bacillus anthracis [17]. 
In this direction, the present study reports the therapeutic 
role of recombinant lethal toxin of Bacillus anthracis, an 
etiological agent of anthrax, on primary mammary ductal 
carcinoma cells.
B. anthracis contains two toxin-encoding plasmids, 
namely, pXO1 and pXO2. The 181 kb pXO1 encodes 
for lethal factor (LF), protective antigen (PA) and 
edema factor (EF). The pXO2 encodes for the bacterial 
capsule, which prevents its phagocytosis by host immune 
cells [18]. Proteolysis of the mature PA, also known 
as PA83, by furin like proteases present in host cells, 
yields a 20 kDa amino-terminal fragment, PA20 and 
a 63 kDa carboxyl-terminal fragment, PA63 [19]. The 
biologically active PA63 forms a heptamer of PA63 
which facilitates the binding and entry of LF and EF 
into the host cell cytoplasm through receptor mediated 
endocytosis [20]. The combination of LF and PA is called 
Lethal Toxin (LeTx). Lethal factor is a zinc dependent 
metalloprotease of 89 kDa size and contains zinc-binding 
motif, HEXXH [21]. The substrates for LF are mitogen-
activated protein kinase (MAPK) kinases (MEKs) [22]. 
It cleaves the N-termini of several intracellular MEK 
members viz. MEK1, MEK2, MEK3, MEK4, MEK6 
and MEK7 [23, 24]. Cleavage of MEKs blocks several 
signal transduction pathways involved in the progression 
of cell cycle including the ERK (extracellular signal-
regulated kinase), p38 and JNK (c-Jun N-terminal kinase) 
pathways [23]. These pathways are involved in cell 
proliferation, differentiation and survival [25]. Unlimited 
cell growth is a typical feature of cancerous tissues and 
is characterized by elevated quantities of MAPK due 
to its role in cell cycle progression [26]. Lethal toxin 
treatment resulted in partial or complete remission in a 
sub-cutaneous xenograft melanoma model [27]. In vivo 
treatment of  fibrosarcoma, the cell dependent on mitogen 
activated protein kinase kinases (MEKs)  revealed 
reduced tumor growth with reduced vascularization upon 
treatment with lethal toxin (LeTx) [28]. The similar 
results have been demonstrated by Liu et al. [29], where 
reduced vascularization in the tumor was observed after 
engineered lethal toxin treatment. MAPKs activation is 
the result of a cascade, which starts with the binding of 
ligand with the c-Met tyrosine kinase receptor (product 
of c-Met proto-oncogene). Upon binding, the c-Met 
receptor dimerizes and both the units auto-phosphorylate 
at tyrosine residues, which in turn creates active binding 
sites for proteins mediating downstream signaling [30]. 
This downstream signaling leads to activation of the 
MAPK [31–34]. Elevated level of c-Met RNA, protein and 
a MET transcriptional profile is linked with the mammary 
tumor progression and c-Met mediated MAPK cascade 
activation (Figure 1) [35–38]. Since LF has the inherent 
property to cleave MEKs, its role in anti-proliferative 
effect on tumors can be hypothesized. Targeting of anthrax 
toxin receptors (ATR) provide a strategy to inhibit tumor 
growth by virtue of targeting tumor vascularization due to 
abundance of ATR on tumor vasculature [39].  
The c-Met receptor is involved in the activation of 
MAPK downstream signaling, growth and differentiation 
and known to express on surface of tumor cells [34]. 
Apart c-Met receptors, several other receptors are also 
known to participate in tumor growth especially with 
regard to breast cancer. The examples are nerve growth 
factor receptor (NGFR) [40, 41], epidermal growth 
factor receptor (EGFR) [42, 43], fibroblast growth 
factor receptors (FGFR) [44, 45] and platelet-derived 
growth factor receptor (PDGFR) [46]. All these are the 
members of tyrosine kinase receptor family and many 
cancer therapies against these receptors are in clinical 
and preclinical status [47–49]. Therefore, the effect of 
recombinant rLF, rPA and LeTx proteins on cultured 
primary mammary ductal adenocarcinoma cells and the 
possible interactions (in silico) of c-Met, NGFR, EGFR, 
FGFR and PDGFR with LF protein were analyzed in the 
present study.
RESULTS
In vitro study on primary mammary tumor cells
Residual mammary tumor biopsy tissues of mid-
aged women (more than 50 years old) were obtained from 
Ayushman Hospital, Bhopal, M.P., India. Histopathology 
reports (Data not shown) of these biopsy samples 
identified as mammary adenocarcinoma (ductal) grade 
III of T2N2 stage. Cytosmears revealed loose cohesive 
clusters of large pleomorphic cells with very few 
infiltrating lymphocytes ensuring proliferative/ anti-
proliferative effect of recombinant LF and PA proteins is 
restricted only to parenchymatous (neoplastic) cells.
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Localization of proteins and yield 
Both the proteins were localized into inclusion 
body fraction and were found specific as indicated by 
western blot analysis (Figure 2). The yield of rLF and 
rPA is 1.5 mg l−1 and 8 mg l−1 of culture respectively 
(rLF-85kDa; rPA-63 kDa).  Both the recombinant 
proteins (rLF and rPA) were biologically active and 
possessing anti-angiogenic effect on CAM, evidenced 
by presence of mesodermal plexus, which failed to 
migrate to ectoderm. Additionally, rPA was found to 
cause hemorrhage in the treated CAM, indicative of its 
biological activity [50].
Effect of recombinant proteins on proliferation 
of mammary tumor cells
The results of the present study showed that 
both rLF and LeTx significantly (p < 0.01) reduced 
the proliferation of mammary tumor cells with mean 
inhibition indices of 28.0 ± 1.37 per cent and 19.6 ± 1.47 
per cent respectively, however treatment with rPA alone 
had no statistically significant anti-proliferative effect 
as indicated by low mean inhibition index of 3.4 ± 3.87 
percent (Figure 3). Since the LF is a metalloprotease and 
having capacity to cleave MAPK, it may be effective 
against several tumors, where cell cycle progression is 
largely dependent on MAPK signaling. 
Figure 1: Plausible mode of functioning of cMET receptor (1) cMET is synthesized by hepatocytes. α subunit is extracellular; 
whereas the β subunit is trans-membrane peptide possessing a kinase domain and docking site for molecule which participate in cell signaling 
and receptor bioactivity (2) upon ligand binding to the cMET receptor, the tyrosine kinase domain is highly phosphorylated at tyrosine 
residue (1234–1235, 1349, 1356 at C terminus of β subunit ) (3) Grb2 effecter binds to phosphorylated tyrosine kinase and RAS guanine 
exchange factor SOS (Son of sevenless) (4) SOS promotes dissociation of GDP from Ras and attachment of GTP thereby activates Ras 
(5) Ras activates Raf and in turn (6) Phosphorylates MEK, followed by phosphorylation of MAPK; LF cleaves MEKs and prevent further 
downstream signaling required for cell proliferation, survival and growth. (7) MAPK activates Myc (7A) and CREB (7B) by phosphorylation 
and (8) These translocates into nucleus and bind to their respective response elements (9) Gab1 interacts with cMet receptor and provide 
binding site for SH2 domain containing proteins (Grb2, PI3K, PLCγ) (10) PI3K phosphorylates Akt, which in turn (11) phosphorylates 
CREB and (12) allow transcription of surviving genes (also 7B) (13) Post phosphorylation C terminus of β subunit of the receptor acts as 
docking site for STAT3  and STAT3 is phosphorylated (14) Dimerized and translocated to nucleus for promoting different gene expressions.
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Here, it is noteworthy that rLF alone has caused 
more inhibition than LeTx, showing biological activity of 
the proteins produced as well as LF exhibited enzymatic 
function independent of PA, which have key role in 
trafficking of LF inside the cell. So presumably, apart from 
PA, another receptor might exist for LF, which led to the 
further investigation through in silico analysis.  
In silico protein docking analysis reveals 
interaction between LF and c-Met receptors
The results of in silico protein docking analysis of 
different receptors with LF have been given in Table 1. In 
the condition of anthrax toxin receptor (ATR) bound PA, 
the PA-LF interaction had 22 H bonds and a free energy 
value of −402.6, indicating higher number of H bonds 
but higher free energy. The software generated docking 
models for LF-PA, LF-PA-ATR and LF-c-Met interactions 
has been depicted in Figure 4A to 4C. Among the other 
receptors, NGFR and HER-1 showed good interactions 
with LF in terms of higher number of H-bonds and higher 
free energy values (Table 1). The present in silico analysis 
using HEX software, revealed a stronger interaction of 
c-Met and LF, suggesting c-Met as alternative receptor for 
LF traffic inside the cell or for modulating the signaling 
cascade upon binding.
The in silico protein docking analysis revealed the 
presence of a stronger interaction between LF and c-Met 
receptor (H bond = 19; and Free energy = −773.96) in 
comparison to that of between LF and PA (H bond = 
12 and Free energy = −420.48). The data indicates that 
LF have stronger affiliation with c-Met in contrast to its 
Figure 2: (A) SDS-PAGE analysis of E. coli expressed 6X His Tagged PA Protein (B) SDS-PAGE analysis of E. coli expressed 6X His 
Tagged LF Protein (Lane 1 corresponds to Rosettablue(DE3)pLysS E.coli cell lysate; lane 2- Total cell pellet of induced culture; Lane 
3-Soluble fraction of cell lysate; Lane 4-Inclusion body fraction of cell lysate; Lane 5-Ni-NTA purified PA/ LF protein; Lane M- Molecular 
weight markers) (C) Western blot analysis of purified PA and LF proteins (~63kDa PA protein and ~85kDa LF protein) (Lane 1 corresponds 
to Purified PA63 protein; lane 2-Purified LF protein; Lane M- Molecular weight markers). 
Table 1: Results of in silico protein docking of receptors involved in cell proliferation and mammary 
tumor with LF using HEX-8 software
S. No. Name of receptor docked with LF protein (1JKY)  
(B. anthracis)
No. of hydrogen bonds Free energy (e-total) 
1 Hepatocyte growth factor receptor (c-Met receptor) (3DKC) 19 −773.96
2 Nerve growth factor receptor TrkA (1HE7) 15 −561.83
3 Human Epidermal Growth Factor HER1 (2ITX) 13 −765.30
4 Human Epidermal Growth Factor HER2 (3PP0) 11 −388.29
5 Human Epidermal Growth Factor HER3 (1M6B) 20 −145.42
6 Human Epidermal Growth Factor HER4 (3BCE) 4 −260.00
7 Human Platelet-Derived Growth Factor (1PDG) 7 −577.35
8 Fibroblast Growth Factor Receptor (1FGK) 2 −412.82
9 Protective antigen (B. anthracis) (4H2A) 12 −420.48
10 Protective antigen bound to Anthrax toxin receptor (1T6B) 22 −402.6
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Figure 3: Decrease in proliferation caused by LeTx and its components was calculated as inhibition index and the values are 
shown as the mean ± SD for a minimum of three independent replicates.
Figure 4: HEX-8 software generated docking model for (A) LF-PA interactions (B) LF-c-Met interactions (C) LF-PA interactions after 
complexing with ATR.
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natural counterpart PA. Since, the number of H bonds 
and minimum free energy are the indicator of stronger 
interaction and higher affinity. The portion of c-Met 
receptor between amino acid residues no. 1061 to 1335 
interact with the amino acid residues no. 409 to 704 of LF 
(Table 2, Figure 5). 
DISCUSSION
Mammary cancer is one of the most common cancers 
present among the females and accounts for approximately 
25% deaths due to cancer. Several FDA approved drugs 
are being given as part of chemotherapy for treating breast 
cancer including Epirubicin, Doxorubicin, Daunorubicin 
and Cyclophosphamide, acting by damaging cancer 
cells and killing them; Everolimus, acting by inhibiting 
mTOR kinase; Pamidronate, acting by limiting the action 
of osteoclastic cells and thereby preventing metastasis in 
bone from mammary tissues, Anastrozole and Raloxifene 
by reducing the relapse of hormone-receptor-positive 
breast cancer; Bevacizumab, the only treatment act by 
targeting angiogenesis in breast cancer; Paraplatin, the 
only platinum base therapy, acting through damaging 
genetic material etc. However, these are all associated 
with some common problems including enhanced risk 
of stroke, headache, nausea, vomiting, abdominal pain, 
joint pain, muscle pain, diarrhea or constipation [51, 52]. 
Trastuzumab, a humanized mAb targeting the HER2 
receptor, displays a good overall survival of patient 
[53] however; pose threat of cardiac dysfunction [54]. 
Another approach to circumvent the mammary tumor 
cell growth is to target MAPK, a key enzyme in the Ras-
Raf-MEK-Extracellular signal Regulated Kinase (ERK) 
kinase pathway, which is constitutively active in tumors 
including mammary tumor [55, 56]. LeTx, a binary toxin 
produced by B. anthracis is catalytically a potent inhibitor 
of the MAPK pathway.  It binds and internalizes within 
most of the tissues but is toxic only to cells dependent 
on MAPK signaling for survival. Considering the fact 
that mammary tumor cells over-express MAPK, which 
is an enzymatic substrate of lethal factor; hence, the 
inhibition in mammary tumor cells proliferation by LeTx 
can be hypothesized. Therefore, the effect of LeTx and 
its components (rLF, rPA) on proliferation of primary 
mammary tumor cells was evaluated in vitro. 
Cell lines are widely accepted models for evaluation 
for antitumor therapeutic drugs, for retaining many 
genetic, epigenetic and gene expression features [57], 
but are more complex than tumor itself due to extensive 
chromosomal rearrangements, oncogene mutations, 
and multiple sites of allelic loss, gene amplification and 
probable change in some cellular pathways [58]. The 
difference in degree of aneuploidy and steroid receptor 
status between breast tumor and breast cancer cell lines 
[59–61] makes cell lines non-representative of the most 
common diverse type of tumors.
Different concentrations of PA and LF, ranging 
from 100 ng to 1 µg [62–66], have been used previously 
to see their cytotoxic effect on LeTx sensitive mouse 
macrophage like cell lines RAW264.7 and J774A and at 
this concentrations cytotoxicity was observed. Though 
cytotoxic dose of LeTx on mammary tumor cells is not 
known, a dose of 50 ng of lethal factor, nontoxic even 
to LeTx sensitive cells, was used, to be assured that the 
effect of the recombinant protein on primary mammary 
cells is attributed to enzymatic or other cellular function 
Table 2: The suitable model for the site of interaction; between the amino-acid residues of c-Met 
receptor and LF using ClusPro















and not due to cytotoxicity. The LF to PA ratio ranging 
from 1:3 to 1:5 has been demonstrated to have maximum 
anti-proliferative activity on melanoma tumor [67]. This 
information support the explanation of dosage of rLF to 
rPA in LeTx used in the present study (1:3 with 50 and 
150 ng of each antigen respectively).
Inhibition in proliferation of mammary tumor cells 
by LF and LeTx in this study (inhibition indices 28 and 
19%) demonstrates the potential use of LF and LeTx as 
therapeutic agent against tumors. Tumor endothelium 
marker-8 (TEM-8) and capillary morphogenesis 
protein-2 (CMG2) are the two types of ATR present on 
the surface of host cells. TEM8 is selectively upregulated 
in endothelial cells during blood vessel formation and in 
endothelial cells of neoplastic tissue; therefore toxicity of 
lethal toxin of B. anthracis may be targeted specifically 
to growing tumor vasculature [39]. This data further may 
be exploited in targeting solid tumors. Further studies are 
required to test their in vivo efficacy. Current literature on 
anthrax toxin activities states that LF and EF as individual 
proteins are inactive and they become functional only 
after binding to PA as binary toxin (PA + LF = LeTx; 
PA + EF = EdTx) [68, 69]. Protective antigen has been 
long considered as trafficking moiety facilitating entry 
of LF and EF into the cells through clathrin, actin and 
unconventional receptor mediated endocytosis [39, 70]. 
In a previous study, intracellular expression of LF in 
human lung adenocarcinoma cell line was found to cause 
cytotoxic effect [71]. Contrary to the existing knowledge 
of PA dependent trafficking of LF, the higher inhibition 
index observed in the study for rLF alone as compared 
to that of LeTx is indicative of enzymatic activity of LF 
alone without the need of PA.
On the basis of above results, PA independent 
receptor mediated endocytosis or modulation of signal 
transduction cascade via binding to other unknown 
moieties can be hypothesized.  To elucidate the possible 
interaction of LF with other cellular receptors i.e. 
c-Met, NGF, EGFR, FGF and PDGF, predominantly 
overexpressing on mammary tumor cells were checked 
in silico. NGF is reported to participate in neuronal 
cell survival and differentiation and there are growing 
evidences of role of NGF as major stimulator of breast 
cancer cell growth. The action of NGF is mediated 
by TrkA (tyrosine kinase receptor family) and p75NT 
(tumor necrosis factor receptor family) [40]. TrkA also 
known as high affinity nerve growth factor receptor 
and is major receptor [72]. Upon binding with ligand, it 
undergoes autophosphorylation and cascade of MAPK 
phosphorylation starts. p75NTR is a minor receptor which 
upon interacting with TrkA receptor, form high-affinity 
binding sites for NGF [73, 74]. Being major receptor, 
TrkA receptor interaction was taken into account. It 
showed 15 hydrogen bonds and -561.83 of free energy. 
The second receptor, epidermal growth factor receptor 
(EGFR) is observed to be over expressed in all subtypes 
of breast cancer. The members of the epidermal growth 
factor receptor are EGFR (HER1), HER2 (also known as 
ErbB2), HER3 (also known as ErbB3), and HER4 (also 
known as ErbB4) [42]. Upon growth-factor binding, 
Figure 5: (A) The site of interactions of c-Met receptor with the LF using ClusPro (B) enlarged view of the same.
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EGFR family members homo- or hetero-dimerize and 
activate their cytoplasmic tyrosine kinase domains to 
initiate intracellular signaling [75, 76]. Upon subjecting 
all EGFR interaction with LF, maximum interaction was 
shown by HER1 with 13 hydrogen bonds and −765.30 
of free energy. Though HER3 exhibited more numbers 
of hydrogen bonds (20), but its free energy was more. 
HER2, which is over-expressed in 20% to 25% of breast 
cancers and is the well established therapeutic target in 
breast cancer [77] showed only 11 hydrogen bonds with 
-388.29 energy. HER4 receptor showed even less degree 
of interaction. The PDGF, are tyrosine kinase receptors, 
function in controlling development of mesenchymal cells, 
such as pericytes, fibroblasts and vascular smooth muscle 
cells [78]. In breast cancer, correlation of PDGF β-receptor 
expression is found [79]. The PDGF β-receptor also 
showed less degree of interaction (H bond = 7 with free 
energy = −577.35). FGFR family comprises four members, 
FGFR-1, -2, -3, and -4 [80]. The activation of signalling 
cascade involve binding of ligand to the extracellular 
domain of receptor and phosphorylation of the cytoplasmic 
tail of the receptor followed by activation of rat sarcoma 
mitogen-activated protein kinase (RAS–MAPK) pathway. 
The several studies have identified amplifications 
of FGFR1 in breast cancer [81, 82] and hence included 
in the study, but there are studies disapproving its role in 
cancer progression also [83]. In our study, poor interaction 
of FGFR with LF is observed in silico. The c-Met receptor, 
a product of proto-oncogene c-met [84], is a known 
tyrosine kinase receptor involved in many signaling 
pathways associated with growth, differentiation, motility, 
migration and invasion. Up regulation of c-Met receptor 
and MAPKs activation leading to cell proliferation has 
been reported in progressive mammary tumors [36]. 
Apart mammary cancer [85], cMET has been expressed in 
several cancers including advanced esophageal squamous 
cell carcinoma [86], lung cancer [87], Renal Cancer [88], 
Malignant skin cancer [89], pancreatic cancer [90] etc. 
Recently, inhibition of cMET has been demonstrated to 
display therapeutic effects in ovarian clear cell carcinoma 
(OCCC). Use of cMET inhibitors, like SU11274 or 
crizotinib, induce apoptosis and reduce proliferation of 
OCCC cells. Other inhibitors include other cMET targeting 
therapies for treating cancers including Monoclonal 
antibodies including  Rilotumumab and Onartuzumab; 
Small molecule c-Met tyrosine kinase inhibitors (TKIs) 
including Tivantinib (ARQ197), AMG337 or Foretinib 
and c-Met targeting antibody ABT-700 [91, 92].
In silico docking analysis was performed to 
understand the possible interactions between LF and 
c-Met and compared to LF-PA as well as LF-PA-ATR 
interactions and it revealed a strong interaction between 
LF and c-Met receptor, as evident by presence of higher 
number of H bonds [19] and lower free energy (−773.96) 
in comparison to its natural trafficking molecule PA. The 
higher number of H bonds [22] observed between LF 
and PA bound to ATR may be due to the conformational 
change in PA induced by PA-ATR interaction. Although 
the number of H bonds in the LF-c-Met interaction is less 
than that in the LF-PA-ATR interaction, the presence of 
lower free energy exhibited a thermodynamically more 
stable interaction due to the non-availability of energy 
to collide and react with other molecules. The results of 
this analysis suggests that out of 5 receptors envisaged 
in the study, LF binds with c-Met receptor strongly and 
possibly compete with other ligands which are involved in 
MAPK mediated cell proliferation pathways, leading to an 
inhibitory effect on tumor growth. Though, involvement 
of NGF and HER1 receptors can’t be denied. Hence, 
we suggest c-Met receptor as one of the major possible 
molecule involved in the alternative strategy adapted by 
LF to perform its action in a PA independent manner either 
by modulating cellular signaling cascades or through 
LF internalization. Further studies are required in this 
direction.
MATERIALS AND METHODS
Recombinant B. anthracis proteins
The LF and PA genes were amplified using 
bacterial plasmid DNA as template.  Primer F- 
GCTAGCATTACTTTGAGTGGTCCCGTCTTT; Primer 
R-TCTAGAATGGCTGGTCCCGTTATT and Primer F- 
AGTGCTCTCGAGACGGTTCCAGACCGTGAC Primer 
R–AAATCACGATCGATTACCTTACCTATCTC were 
used for amplification of LF and PA genes respectively. 
After a cloning step in pGEM-T easy vector (Promega, 
Madison, WI, USA) for sequencing, these genes were 
subcloned into pQE-31 (Qiagen, India) for LF gene and 
pET28(c)+ for PA63 (Novagen, Billerica, MA, USA) 
respectively. The constructs were transformed into their 
respective expression host SG13009 and Rosetta blue 
(DE3) codon plus E. coli cells. Recombinant protein 
expression was induced by adding 1mM IPTG and the 
culture was induced for 4 hours. The cells were harvested 
by centrifugation and recombinant proteins were purified 
using Bug buster protein extraction reagent (Novagen). 
Soluble and inclusion body fraction was collected 
separately and run on 12.5% SDS polyacrylamide gel. 
The protein was characterized by western blot analysis 
using polyclonal serum raised in monkey against 
attenuated live anthrax spore vaccine. The recombinant 
proteins were purified using His Bind purification kit 
(Novagen) and subjected to refolding by protein refolding 
kit (Novagen) as per manufacturer protocol [93]. The 
protein was quantified using Qubit protein assay kit (Life 
Technologies, California, US). Biological activity of both 
the proteins was determined in chorioallantoic membrane 
(CAM) of embryonated chicken eggs for their effect on 
process of vascularization.
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In vitro study on primary mammary tumor cells
Residual mammary tumor biopsy tissues were 
provided by Dr. Sunita Yadav, MS, General and Cancer 
surgeon, Ayushman Hospital, Bhopal, M.P., India. The 
tissue were dissected and trypsinized (0.01%) in RPMI 
medium. Cells were resuspended in RPMI medium 
supplemented with 10% FBS and seeded in a 96 well plate 
at a concentration of 5 × 103 cells per well in 100 μl volume. 
Per microscopic field 3-4 infiltrating lymphocytes were 
present. Four test groups were prepared, each comprising 
triplicate wells. 100 µl each of rPA (150 ng/well), in first 
set; rLF (50 ng/well) in second set; and LeTx [mixture 
of rPA (150 ng) + rLF (50 ng)] in third set of experiment 
were added in triplicate in 96 well plate (Nunc). For control 
group, 100 µl RPMI media was added.
The plate was incubated at 37°C in CO2 (5%) 
incubator for 72 h. Then 100 μl of cell suspension was taken 
out and mixed with 50 μl of MTT solution (5 mg ml−1). The 
plate was incubated at 37°C for additional 4 h. Resulting 
formazon crystals were dissolved in 100 μl of DMSO by 
vigorous pipetting and incubated at 37°C for 15 min. Optical 
density (OD) was measured at 492 nm in a multi-well 
ELISA plate reader (Tecan, Japan). Inhibition index was 
calculated from the OD values using the following formula:
� � � � � � � �Inhibitionindex ODof control group ODof treated group
O
= -
Dof control group� � �
The significance of difference between test groups 
was analyzed by student’s t-test and p-value less than 0.01 
was considered as significantly different.
In silico docking analysis
In order to compare and understand the interaction 
of LF (PDB: 1JKY) with PA (pH7.5; pdb-4H2A), PA 
bound to Anthrax Toxin Receptor (ATR) (PDB: 1T6B), 
c-Met (PDB: 3DKC) and other related group of receptors 
(NGFR, EGFR, FGFR and PDGFR); in silico analysis was 
carried out using HEX-8 protein docking software (http://
hex.loria.fr). Number of hydrogen bonds involved in the 
interactions between the docked proteins and the total free 
energy for each interaction were compared. Presence of 
higher number of H bonds and lower free energy indicated 
a stronger interaction between the proteins. The interaction 
between receptors and ligand was also confirmed using 
software ClusPro.
CONCLUSIONS
Results of the present study demonstrated 
the potential of rLF and LeTx for use as alternative 
therapeutics against mammary ductal carcinoma. Since 
mammary tumors are highly heterogeneous, the effect of 
LF and LeTx on other mammary tumor categories, need to 
be evaluated further. As indicated by the higher inhibition 
index observed for rLF alone as compared to that of LeTx, 
possible existence of PA independent modes of action of 
LF such as receptor mediated PA independent endocytosis 
or modulation of signal transduction cascade via other 
unknown interactions was hypothesized. In silico docking 
analysis also revealed the plausible existence of c-Met as 
an alternative receptor for LF to mediate and modulate PA 
independent signal transduction.
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